Your browser is no longer supported. Please, upgrade your browser.
XON Intrexon Corporation daily Stock Chart
XON [NASD]
Intrexon Corporation
Index- P/E- EPS (ttm)-3.58 Insider Own0.40% Shs Outstand178.13M Perf Week-13.24%
Market Cap1.05B Forward P/E- EPS next Y-0.99 Insider Trans-13.78% Shs Float137.58M Perf Month2.79%
Income-493.60M PEG- EPS next Q-0.27 Inst Own75.20% Short Float23.85% Perf Quarter11.53%
Sales125.50M P/S8.37 EPS this Y67.70% Inst Trans0.05% Short Ratio26.53 Perf Half Y-29.85%
Book/sh1.48 P/B3.99 EPS next Y22.00% ROA-73.50% Target Price10.00 Perf Year-23.97%
Cash/sh0.60 P/C9.91 EPS next 5Y2.40% ROE-166.80% 52W Range3.95 - 8.77 Perf YTD7.66%
Dividend- P/FCF- EPS past 5Y-22.90% ROI-84.20% 52W High-32.73% Beta2.36
Dividend %- Quick Ratio1.70 Sales past 5Y46.50% Gross Margin50.90% 52W Low49.37% ATR0.47
Employees882 Current Ratio1.90 Sales Q/Q-29.00% Oper. Margin- RSI (14)46.58 Volatility9.11% 8.18%
OptionableYes Debt/Eq0.95 EPS Q/Q21.60% Profit Margin- Rel Volume0.99 Prev Close5.89
ShortableYes LT Debt/Eq0.81 EarningsFeb 11 BMO Payout- Avg Volume1.24M Price5.90
Recom2.70 SMA20-4.07% SMA500.61% SMA200-1.22% Volume1,227,241 Change0.25%
Mar-01-19Downgrade Northland Capital Outperform → Market Perform
Jul-17-18Resumed Stifel Buy $72
Jul-16-18Downgrade BofA/Merrill Neutral → Underperform
Nov-10-17Reiterated Stifel Buy $57 → $39
Nov-10-17Reiterated Stifel Buy $39 → $57
Dec-29-16Initiated Northland Capital Outperform $40
May-03-16Initiated JMP Securities Mkt Outperform
Mar-01-16Reiterated Stifel Buy $69 → $57
Mar-01-16Reiterated Mizuho Neutral $28 → $29
Jan-25-16Reiterated Mizuho Neutral $42 → $28
Nov-11-15Upgrade Mizuho Underperform → Neutral $45 → $42
Oct-19-15Reiterated Wunderlich Buy $70 → $50
Oct-14-15Initiated BofA/Merrill Neutral $35
Sep-21-15Initiated Stifel Buy $69
Aug-11-15Downgrade Mizuho Neutral → Underperform $45
Aug-11-15Downgrade JP Morgan Overweight → Neutral
Jul-27-15Reiterated Wunderlich Buy $55 → $70
Jun-09-15Initiated Wunderlich Buy $55
Mar-10-15Downgrade Mizuho Buy → Neutral $14
Mar-03-15Reiterated Mizuho Buy $32 → $50
Jan-09-20 07:30AM  Triple-Gene Announces Presentation at Upcoming Biotech Showcase Investor Conference PR Newswire
Jan-07-20 09:51AM  Intrexon's Blood Cancer Drug Gets Orphan Drug Status From FDA Zacks
Jan-06-20 05:14PM  Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug. American City Business Journals
07:30AM  Precigen Receives FDA Orphan Drug Designation for PRGN-3006 UltraCAR-T in Patients with Acute Myeloid Leukemia (AML) PR Newswire
Jan-03-20 10:25AM  Is the Options Market Predicting a Spike in Intrexon (XON) Stock? Zacks
Jan-02-20 05:01PM  Intrexon changing name, raising $175M to laser focus on health care American City Business Journals +7.85%
10:33AM  Darling Ingredients Acquires 100% of EnviroFlight PR Newswire
08:53AM  Is Intrexon Corporation (NASDAQ:XON) Excessively Paying Its CEO? Simply Wall St.
07:55AM  Intrexon To Achieve $175M Cash Goal, Appoints Helen Sabzevari, PhD, As New President And CEO And Will Change Name To Precigen To Reflect Healthcare Focus PR Newswire
Dec-19-19 09:45PM  Hedge Funds Are Betting On Intrexon Corp (XON) Insider Monkey
Dec-06-19 08:00AM  12 Biotech Stocks Primed For A Short Squeeze Benzinga
Nov-18-19 07:30AM  Triple-Gene Presented Preliminary Phase 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN4001 for Treatment of Heart Failure at American Heart Association Annual Meeting PR Newswire
Nov-17-19 08:42AM  The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down Benzinga
Nov-13-19 09:33AM  Intrexon (XON) Reports Narrower-Than-Expected Loss in Q3 Zacks +9.18%
Nov-12-19 07:30AM  Intrexon Reports Third Quarter 2019 Financial Results PR Newswire -9.40%
Nov-07-19 07:30AM  Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN4001, First Multigenic Investigational Therapeutic Candidate for Treatment of Heart Failure PR Newswire
Nov-04-19 04:05PM  Intrexon to Announce Third Quarter Financial Results on November 12th PR Newswire
Oct-27-19 02:00PM  Is Intrexon Corp (XON) Going To Burn These Hedge Funds ? Insider Monkey
Oct-03-19 06:06AM  Have Insiders Been Selling Intrexon Corporation (NASDAQ:XON) Shares This Year? Simply Wall St.
Sep-26-19 07:30AM  David H. Witte to lead MBP Titan LLC PR Newswire
Sep-24-19 04:00AM  Next Green Wave Achieves Operational Milestones For Intrexons Botticelli Cannabis Plantlet Production GlobeNewswire
Aug-29-19 09:01AM  Teladoc Gains on Growing Acceptance for TeleHealth Services Zacks
Aug-19-19 07:30AM  ActoBio Therapeutics Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of Gluten PR Newswire
05:59AM  Introducing Intrexon (NASDAQ:XON), The Stock That Tanked 77% Simply Wall St.
Aug-15-19 08:45PM  Edited Transcript of XON earnings conference call or presentation 8-Aug-19 9:30pm GMT Thomson Reuters StreetEvents
Aug-12-19 03:21AM  Intrexon Corp (XON) Q2 2019 Earnings Call Transcript Motley Fool
Aug-09-19 10:59AM  Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2 Zacks -8.79%
Aug-08-19 05:15PM  Intrexon Reports Second Quarter and First Half 2019 Financial Results PR Newswire
Aug-05-19 07:30AM  Precigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T in Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer PR Newswire -7.39%
Aug-01-19 10:33AM  Earnings Preview: Intrexon (XON) Q2 Earnings Expected to Decline Zacks
07:30AM  Intrexon to Announce Second Quarter and First Half 2019 Financial Results on August 8th PR Newswire
Jul-09-19 04:44PM  Here's Why Intrexon Jumped 58% in June Motley Fool
Jul-05-19 07:18AM  What Does Intrexon Corporation's (NASDAQ:XON) Balance Sheet Tell Us About It? Simply Wall St.
Jul-01-19 07:30AM  ActoBio Therapeutics Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 Diabetes PR Newswire
Jun-26-19 07:30AM  Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS) PR Newswire
Jun-25-19 08:32AM  Do Options Traders Know Something About Intrexon (XON) Stock We Don't? Zacks
Jun-19-19 09:40AM  Intrexon Up on Striking 100M Cannabinoid Deal With Surterra Zacks
Jun-18-19 03:46PM  Why Intrexon Stock Popped Today Motley Fool +13.16%
11:19AM  Intrexon Strikes $100M Partnership With Surterra For Cannabinoid Production Benzinga
09:05AM  Intrexon Corporation and Surterra Wellness Partner in $100mm Deal to Advance Commercial Scale Fermentation-based Cannabinoid Production PR Newswire
Jun-13-19 07:30AM  Intrexon's Subsidiary Precigen to Present at the JMP Securities Life Sciences Conference PR Newswire +7.66%
Jun-10-19 07:15PM  Intrexon Corp (XON) CEO Randal J Kirk Bought $2.5 million of Shares GuruFocus.com
11:59AM  Weekly CEO Buys Highlight GuruFocus.com
Jun-08-19 09:30AM  Intrexon (XON) Up 24.7% Since Last Earnings Report: Can It Continue? Zacks
Jun-04-19 07:15PM  Intrexon Corp (XON) CEO Randal J Kirk Bought $998,306 of Shares GuruFocus.com
Jun-03-19 12:45PM  Weekly CEO Buys Highlight GuruFocus.com +6.61%
08:30AM  Oxitec Successfully Completes First Field Deployment of 2nd Generation Friendly Aedes aegypti Technology PR Newswire
07:30AM  Intrexon Announces Advances in Non-Browning GreenVenus Romaine Lettuce PR Newswire
06:43AM  Notable Insider Buys This Past Week: Coty, Zillow and More Benzinga
May-31-19 10:45AM  Intrexon CEO Made Big Open-Market Bets In May Benzinga
May-30-19 10:15PM  Intrexon Corp (XON) CEO Randal J Kirk Bought $2.4 million of Shares GuruFocus.com
08:44AM  Fibrocell Up on FDA Designation for Gene Therapy Candidate Zacks
May-29-19 08:00AM  Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB GlobeNewswire
May-28-19 12:41PM  Weekly CEO Buys Highlight GuruFocus.com
07:30AM  Intrexon to Participate in 2019 BIO International Convention PR Newswire
May-24-19 09:15PM  Intrexon Corp (XON) CEO Randal J Kirk Bought $1.9 million of Shares GuruFocus.com
May-21-19 11:15PM  Intrexon Corp (XON) CEO Randal J Kirk Bought $2.9 million of Shares GuruFocus.com
11:41AM  Weekly CEO Buys Highlight GuruFocus.com
May-20-19 07:22PM  Cramer's lightning round: I feel bad if you own Intrexon It's a loser CNBC
02:55PM  Intrexon CEO buys up more company shares American City Business Journals
May-15-19 08:15PM  Intrexon Corp (XON) CEO Randal J Kirk Bought $5.5 million of Shares GuruFocus.com +6.29%
May-13-19 07:30AM  Intrexon to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference PR Newswire
May-10-19 08:34AM  Intrexon (XON) Reports In-Line Q1 Loss, Misses on Revenues Zacks
May-09-19 04:10PM  Intrexon Reports First Quarter 2019 Financial Results PR Newswire
May-02-19 04:30PM  AquaBounty Technologies, Inc. Announces Results for the Quarter Ended March 31, 2019, and Company Update GlobeNewswire
04:05PM  Intrexon to Release First Quarter 2019 Financial Results on May 9th PR Newswire
01:53PM  Heres What Hedge Funds Think Of Intrexon Corp (XON) Insider Monkey
10:32AM  Analysts Estimate Intrexon (XON) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-29-19 07:30AM  Intrexon and Xogenex Present at American Society of Gene and Cell Therapy Annual Meeting PR Newswire
Apr-25-19 04:05PM  Precigen Opens Gene and Cell Therapy Manufacturing Facility in Germantown, Maryland PR Newswire
Apr-17-19 04:45PM  AquaBounty Technologies, Inc. Announces Exercise of Option to Purchase Additional Shares GlobeNewswire -12.43%
Apr-16-19 10:59AM  Fibrocell Out-licenses Skin Disease Gene Therapy, Stock Rises Zacks +6.51%
07:30AM  Oxitec Signs New Multi-year Development Agreement to Apply 2nd Generation Technology to Control Soybean Looper PR Newswire
Apr-15-19 06:30AM  Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy GlobeNewswire
Apr-10-19 07:30AM  Intrexon to Highlight Microbial Cannabinoid Production Platform at the Paradigm Capital Biosynthesis Conference PR Newswire
Apr-09-19 04:00PM  AquaBounty Technologies, Inc. Announces Closing of Public Offering of Common Stock GlobeNewswire -5.94%
07:30AM  Oxitec Advances Self-Limiting Fall Armyworm Control Solution to Next Phase of Development PR Newswire
Apr-08-19 08:28AM  Why Intrexon Stock Dropped 34% in March Motley Fool
Apr-04-19 09:55PM  AquaBounty Technologies, Inc. Announces Pricing of $5.75 Million Public Offering of Common Stock GlobeNewswire
04:08PM  AquaBounty Technologies, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
Apr-03-19 07:30AM  Intrexon Intensifies Focus on Healthcare, Forms Two Units and Streamlines Management PR Newswire
Apr-02-19 07:00AM  AquaBounty Technologies, Inc. Environment and Climate Change Canada Approves Rollo Bay Facility for Commercial Production of AquAdvantage Salmon GlobeNewswire
Mar-30-19 09:30AM  Why Is Intrexon (XON) Down 34% Since Last Earnings Report? Zacks
Mar-22-19 04:00AM  Next Green Wave's Nursery Botticelli(TM) Research & Development Program Begins Newsfile -6.77%
Mar-21-19 04:01PM  AquaBounty Technologies, Inc. Announces Closing of Public Offering of Common Stock GlobeNewswire +5.69%
Mar-19-19 06:00AM  AquaBounty Technologies, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
Mar-18-19 04:00PM  AquaBounty Technologies, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
Mar-12-19 07:20AM  Jim Cramer Shares His Thoughts On Ambarella, Centurylink, Chipotle And More Benzinga
Mar-08-19 03:19PM  AquaBounty Technologies, Inc. - FDA Lifts Import Alert on AquAdvantage Salmon GlobeNewswire
Mar-07-19 05:00PM  AquaBounty Technologies, Inc. Results for the year ended December 31, 2018 GlobeNewswire +9.11%
Mar-05-19 06:41PM  Edited Transcript of XON earnings conference call or presentation 28-Feb-19 10:30pm GMT Thomson Reuters StreetEvents +21.26%
04:01PM  Here's What Caused Intrexon's 21% Rally Today Motley Fool
07:45AM  Market Trends Toward New Normal in Ritchie Bros. Auctioneers, Empire State Realty Trust, Synergy Resources, IQVIA, Intrexon, and Denbury Resources Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Mar-04-19 04:47PM  Here's Why Intrexon Crashed (Again) Today Motley Fool -18.18%
04:03PM  Intrexon, Surterra Wellness Collaborate On Plant Propagation For Cannabis Cultivation Benzinga
07:30AM  Intrexon and Surterra Wellness to Collaborate on Botticelli Next Generation Plant Propagation for Cannabis Cultivation PR Newswire
Mar-01-19 09:16AM  Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4 Zacks -36.51%
01:40AM  Intrexon Corp (XON) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-28-19 04:15PM  Intrexon Reports 2018 Fourth Quarter and Year End Financial Results PR Newswire
Feb-27-19 07:30AM  Intrexon to Showcase Differentiated Methane Bioconversion Platform at Upcoming Petroleum Industry Events PR Newswire
Intrexon Corporation engages in the engineering and industrialization of biology in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. It provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of artificial additives; genetically engineered swine for medical and genetic research; commercial aquaculture products; and preservation and cloning technologies. The company also offers UltraVector platform that enables design and assembly of gene programs that facilitate control over the quality, function, and performance of living cells; and RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression. In addition, it provides AttSite Recombinases, which allows stable, targeted gene integration and expression; LEAP automated platform to identify and purify cells of interest, such as antibody expressing cells and stem cells; ActoBiotics platform for targeted in situ expression of proteins and peptides from engineered microbes; and AdenoVerse technology platform for tissue specificity and target selection. The company serves the health, food, energy, and environment markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Genopaver, LLC; Fibrocell Science, Inc.; Persea Bio, LLC; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Wellness. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bostick ThomasChief Operating OfficerJan 06Sale5.836,53338,08374,280Jan 07 05:15 PM
Reed Thomas D.Chief Science OfficerJan 06Sale5.835,41631,571148,888Jan 07 05:14 PM
Perez Jeffrey ThomasSVP, IP AffairsJan 06Sale5.836,53338,08380,948Jan 07 05:14 PM
Lehr Donald P.Chief Legal OfficerJan 06Sale5.837,15541,70893,991Jan 07 05:14 PM
Sabzevari HelenPresident and CEOJan 06Sale5.836,73239,24398,002Jan 07 05:13 PM
Sterling Rick L.Chief Financial OfficerJan 06Sale5.836,53338,082143,032Jan 07 05:12 PM
Sterling Rick L.Chief Financial OfficerJan 03Sale5.773,56420,564130,625Jan 06 04:16 PM
Reed Thomas D.Chief Science OfficerJan 03Sale5.772,98617,229135,364Jan 06 04:15 PM
Sabzevari HelenPresident and CEOJan 03Sale5.773,88622,42187,067Jan 06 04:16 PM
Perez Jeffrey ThomasSVP, IP AffairsJan 03Sale5.773,56420,56468,541Jan 06 04:14 PM
Lehr Donald P.Chief Legal OfficerJan 03Sale5.773,88622,42282,206Jan 06 04:14 PM
Bostick ThomasChief Operating OfficerJan 03Sale5.773,56420,56461,873Jan 06 04:15 PM
Sterling Rick L.Chief Financial OfficerJan 02Sale5.604,36624,450124,423Jan 03 04:33 PM
Reed Thomas D.Chief Science OfficerJan 02Sale5.603,53319,785128,584Jan 03 04:32 PM
Sabzevari HelenPresident and CEOJan 02Sale5.604,83027,04881,187Jan 03 04:32 PM
Lehr Donald P.Chief Legal OfficerJan 02Sale5.604,83027,04876,326Jan 03 04:31 PM
Perez Jeffrey ThomasSVP, IP AffairsJan 02Sale5.604,36624,45062,339Jan 03 04:31 PM
Bostick ThomasChief Operating OfficerJan 02Sale5.604,36624,45055,671Jan 03 04:30 PM
Perez Jeffrey ThomasSVP, IP AffairsOct 01Sale5.504,52124,84752,365Oct 02 05:25 PM
Bostick ThomasChief Operating OfficerOct 01Sale5.504,52124,84745,697Oct 02 05:25 PM
Sabzevari HelenPresident, Precigen, Inc.Oct 01Sale5.505,00527,50771,677Oct 02 05:25 PM
Sterling Rick L.Chief Financial OfficerOct 01Sale5.504,52124,847114,449Oct 02 05:25 PM
Reed Thomas D.Chief Science OfficerOct 01Sale5.503,65820,104117,777Oct 02 05:25 PM
Lehr Donald P.Chief Legal OfficerOct 01Sale5.505,00127,48566,816Oct 02 05:24 PM
Sabzevari HelenPresident, Precigen, Inc.Jul 18Sale7.478,48463,37762,341Jul 19 05:21 PM
Walsh Robert F. IIISVP, Energy & Fine Chem.Jul 01Sale7.765,00738,85428,816Jul 02 07:13 PM
Sabzevari HelenPresident, Precigen, Inc.Jul 01Sale7.764,82237,41945,825Jul 02 07:12 PM
Sterling Rick L.Chief Financial OfficerJul 01Sale7.764,35933,826104,629Jul 02 07:13 PM
Perez Jeffrey ThomasSVP, IP AffairsJul 01Sale7.764,35933,82642,545Jul 02 07:11 PM
Reed Thomas D.Chief Science OfficerJul 01Sale7.763,52727,370107,094Jul 02 07:12 PM
Bostick ThomasChief Operating OfficerJul 01Sale7.764,35933,82635,877Jul 02 07:10 PM
Lehr Donald P.Chief Legal OfficerJul 01Sale7.764,82237,41957,476Jul 02 07:11 PM
KIRK RANDAL JChief Executive OfficerJun 07Buy5.26148,237779,7271,142,758Jun 10 05:20 PM
KIRK RANDAL JChief Executive OfficerJun 07Buy5.26222,3551,169,58718,268,451Jun 10 05:19 PM
KIRK RANDAL JChief Executive OfficerJun 06Buy5.23173,942909,7171,113,111Jun 10 05:20 PM
KIRK RANDAL JChief Executive OfficerJun 06Buy5.23260,9131,364,57518,138,648Jun 10 05:19 PM
KIRK RANDAL JChief Executive OfficerJun 04Buy5.1745,120233,2701,078,323Jun 04 06:05 PM
KIRK RANDAL JChief Executive OfficerJun 04Buy5.1767,679349,90017,986,337Jun 04 06:01 PM
KIRK RANDAL JChief Executive OfficerMay 31Buy4.7890,428432,2461,069,299Jun 04 06:05 PM
KIRK RANDAL JChief Executive OfficerMay 31Buy4.78135,642648,36917,902,546Jun 04 06:01 PM
KIRK RANDAL JChief Executive OfficerMay 30Buy4.79205,060982,2371,051,213May 30 07:47 PM
KIRK RANDAL JChief Executive OfficerMay 30Buy4.79307,5921,473,36617,823,362May 30 07:42 PM
KIRK RANDAL JChief Executive OfficerMay 29Buy4.68125,120585,5621,010,201May 30 07:47 PM
KIRK RANDAL JChief Executive OfficerMay 29Buy4.68187,679878,33817,643,801May 30 07:42 PM
KIRK RANDAL JChief Executive OfficerMay 24Buy4.6872,430338,972985,177May 24 07:29 PM
KIRK RANDAL JChief Executive OfficerMay 24Buy4.68108,645508,45917,534,241May 24 07:23 PM
KIRK RANDAL JChief Executive OfficerMay 23Buy4.6785,750400,453970,691May 24 07:29 PM
KIRK RANDAL JChief Executive OfficerMay 23Buy4.67128,626600,68317,470,818May 24 07:23 PM
KIRK RANDAL JChief Executive OfficerMay 22Buy4.70115,187541,379953,541May 24 07:29 PM
KIRK RANDAL JChief Executive OfficerMay 22Buy4.70172,779812,06117,395,730May 24 07:23 PM
KIRK RANDAL JChief Executive OfficerMay 21Buy4.7460,223285,457930,504May 21 08:07 PM
KIRK RANDAL JChief Executive OfficerMay 21Buy4.7490,335428,18817,294,866May 21 08:05 PM
KIRK RANDAL JChief Executive OfficerMay 20Buy4.63301,6701,396,732918,459May 21 08:07 PM
KIRK RANDAL JChief Executive OfficerMay 20Buy4.63452,5022,095,08417,242,131May 21 08:05 PM
KIRK RANDAL JChief Executive OfficerMay 17Buy4.6960,530283,886858,125May 21 08:07 PM
KIRK RANDAL JChief Executive OfficerMay 17Buy4.6990,794425,82416,977,975May 21 08:05 PM
KIRK RANDAL JChief Executive OfficerMay 15Buy4.59471,0772,162,24316,924,973May 15 05:36 PM
KIRK RANDAL JChief Executive OfficerMay 15Buy4.59314,0501,441,490846,019May 15 05:38 PM
KIRK RANDAL JChief Executive OfficerMay 14Buy4.37221,251966,86716,649,972May 15 05:36 PM
KIRK RANDAL JChief Executive OfficerMay 14Buy4.37147,500644,575783,209May 15 05:38 PM
KIRK RANDAL JChief Executive OfficerMay 13Buy4.25565,3992,402,94616,520,814May 15 05:36 PM
KIRK RANDAL JChief Executive OfficerMay 13Buy4.25376,9321,601,961753,709May 15 05:38 PM
KIRK RANDAL J10% OwnerApr 03Sale0.6595,24161,90762,342Apr 03 05:13 PM
KIRK RANDAL J10% OwnerApr 02Sale0.6613,6469,00688,422Apr 03 05:13 PM
KIRK RANDAL J10% OwnerApr 01Sale0.6741,67827,92492,159Apr 03 05:13 PM
MITCHELL DEAN JDirectorMar 12Option Exercise3.178,90628,23241,750Mar 12 07:11 PM
Reed Thomas D.Chief Science OfficerMar 05Sale4.662,30010,71841,705Mar 06 09:07 PM
Reed Thomas D.Chief Science OfficerMar 04Sale4.18225,500943,69044,005Mar 06 09:07 PM
ALVAREZ CESAR LDirectorFeb 19Option Exercise3.172,9689,409117,817Feb 21 04:46 PM
Frank StevenDirectorFeb 12Option Exercise3.172,9689,409195,225Feb 14 04:41 PM
Reed Thomas D.Chief Science OfficerFeb 07Option Exercise3.172,9699,41296,280Feb 11 04:57 PM